Preclinical
-
AstraZeneca strengthens its cardiovascular pipeline with agreement for a pre-clinical novel lipid-lowering therapy
Congratulations to CSPC and AstraZeneca!
-
AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease
If you are looking for a promising TL1A product, please contact DrugTimes BD Team (BD@drugtimes.cn)
